Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide and empagliflozin combinations in newly diagnosed overweight or obese type 2 diabetes
ChiCTR2000030904Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Apr 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin, liraglutide and empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: HbA1c at 24 week and Matsuda index at 24 week. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000030904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030904.